HRTXMEDIUM SIGNALFINANCIAL10-K

HRTX showed improved operating performance with meaningfully reduced operating losses, though this was offset by higher interest expenses leading to increased net losses.

The substantial improvement in operating income suggests the company's commercialization efforts for ZYNRELEF and other products are gaining traction, with reduced R&D spending also contributing to operational efficiency. However, rising interest expenses and deteriorating operating cash flow indicate continued funding pressures that investors should monitor closely.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

The company demonstrated mixed financial performance with operating losses improving substantially from -$11.5M to -$2.5M, aided by a 25% reduction in R&D expenses. However, net income declined to -$20.2M due to higher interest expenses, while operating cash flow deteriorated to -$27.6M. The balance sheet showed growth in key working capital items, with inventory increasing notably to $92.7M and accounts receivable growing 13.6%, suggesting increased business activity though at the cost of cash generation.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-81.4%
$1.7M→$317K

Capex reduced 81.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
+78%
-$11.5M→-$2.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
+74.5%
$53.2M→$92.7M

Inventory surged 74.5% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
+56.3%
$2.5M→$3.9M

Interest expense surged 56.3% — significant debt increase or rising rates materially impacting earnings.

Net Income
P&L
-48.7%
-$13.6M→-$20.2M

Net income declined 48.7% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
-25.5%
$16.7M→$12.4M

R&D spending cut 25.5% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
-22.5%
-$22.5M→-$27.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Assets
Balance Sheet
+13.9%
$209.0M→$238.1M

Current assets grew 13.9% — improving short-term liquidity or inventory/receivables build.

Accounts Receivable
Balance Sheet
+13.6%
$78.9M→$89.6M

Receivables grew 13.6% — monitor days sales outstanding for collection efficiency.

Cash & Equivalents
Balance Sheet
+11%
$25.8M→$28.6M

Cash grew 11% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 13, 2026, there were 188,537,136 shares of the Company s common stock ($0.01 par value) outstanding.
In some cases, you can identify forward-looking statements by the use of the words "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "might," "project," "should," "will," "would," and other expressions that predict or indicate future events and trends and which do not relate to historical matters.
Food and Drug Administration ("FDA") and to obtain favorable results and comply with standard postmarketing requirements, including U.S.
3 PART I In this Annual Report on Form 10-K, all references to "Heron," the "Company," "we," "us," "our" and similar terms refer to Heron Therapeutics, Inc.
ZYNRELEF is approved for use in adults for postsurgical analgesia for up to 72 hours after soft tissue and orthopedic surgical procedures including foot and ankle, and other orthopedic surgical procedures in which direct exposure to articular cartilage is avoided.
+7 more — sign up free →
REMOVED
As of February 13, 2025, there were 152,329,588 shares of the Company s common stock ($0.01 par value) outstanding.
We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.
In some cases, you can identify forward-looking statements by the use of the words believe, expect, anticipate, intend, estimate, project, will, would, could, should, may, might, plan, assume and other expressions that predict or indicate future events and trends and which do not relate to historical matters.
Factors that might cause these differences include the following: our ability to successfully commercialize, market and achieve market acceptance of ZYNRELEF (bupivacaine and meloxicam) extended-release solution ( ZYNRELEF ), APONVIE (aprepitant) injectable emulsion ( APONVIE ), CINVANTI (aprepitant) injectable emulsion ( CINVANTI ), and SUSTOL (granisetron) extended-release injection ( SUSTOL and together with ZYNRELEF, APONVIE and CINVANTI, our "Products") in the United States ( U.S.
Food and Drug Administration ( FDA ) and to obtain favorable results and comply with standard postmarketing requirements, including U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →